Researchers discovered a vulnerability in viral enzymes that could lead to novel treatments for diseases as diverse as COVID and Ebola, while also minimizing side effects and reducing the odds of drug resistance.
Thomas Tuschl has devoted his career to making discoveries that bridge the gap between bench and business—and have resulted in entirely new classes of drugs.